McKesson Corporation (MCK)
MCK Stock Down Despite Latest Partnership to Boost SCD Treatment
The availability of the FDA-approved drug via McKesson's cell and gene therapies business is expected to give patients improved treatment options for SCD.
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
McKesson (MCK) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Here is Why Growth Investors Should Buy McKesson (MCK) Now
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why McKesson (MCK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven by specialty distribution and retail national account customers.
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday.
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson (MCK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) Q2 Earnings and Revenues Beat Estimates
McKesson (MCK) came out with quarterly earnings of $7.07 per share, beating the Zacks Consensus Estimate of $6.89 per share. This compares to earnings of $6.23 per share a year ago.
